Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib and Bevacizumab in ALK-Rearranged TP53 Mutated NSCLC
NCT05491811Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-free Survival rate at 12 months. Started Aug 2022; status: active, not recruiting.
02
Drugs
ensartinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05491811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491811.